Journal of Clinical Oncology
Articles in this Issue
Bridging gaps: Evaluating the impact of urban lung cancer screening on diverse populations.
e13835 Background: Lung cancer (LC) screening reduces mortality in high-risk populations, yet disparities persist, particularly among Hispanic individuals...
Lorlatinib therapy in relapsed/refractory ALK+ lymphomas previously treated with tyrosine kinase inhibitors.
7054 Background: ALK+ Lymphomas are aggressive diseases with poor prognosis when chemoimmunotherapy (CIT) and Crizotinib fail. Lorlatinib is a 3rd-generat...
Leveraging the power of diagnostic metrics to competency based medical education (CBME) implementation in medical oncology (MO) across Canada.
9025 Background: MO training programs across Canada implemented CBME in 2018. Early implementation focused primarily on immediate “structural” changes, an...
Giredestrant (G) with atezolizumab (ATEZO), and/or abemaciclib (ABEMA) in patients (pts) with ER+/HER2– locally advanced/metastatic breast cancer (LA/mBC): Interim analysis (IA) from the phase I/II MORPHEUS Breast Cancer study.
1061 Background: Endocrine therapy (ET) + a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is a therapeutic mainstay for first-line treatment (tx) of ER+...
Association between gastrostomy and clinical outcomes including septicemia, weight loss, mortality, and discharge dispositions among metastatic head and neck cancer patients hospitalized for treatment in the US.
e18033 Background: The insertion of a gastrostomy tube provides nutritional support to a large number of patients diagnosed with head and neck cancer (HNC...
Efficacy and safety of donafenib combined with PD-(L)1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients.
e16178 Background: Previous research suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS, OS, and ORR versus TACE monotherapy...
Effcacy and safety results of a multi-center phase I/II study of utidelone capsule, a novel oral microtubule inhibitor.
e13110 Background: Utidelone is a best-in-class novel microtubule inhibitor that offers several advantages including improved efficacy and safety, broader...
Harnessing diversity: Examining the feasibility of conducting oncology trials in South Africa.
e23028 Background: The global landscape of oncology research has increasingly recognized the importance of including diverse populations in clinical trial...
Testing and treatment patterns in <i>KRAS</i> mutant mNSCLC: Results from the MYLUNG Consortium.
e20639 Background: The Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic (MYLUNG) Consortium assesses biomarker testin...
Real-world analysis of primary tumor transcriptomes in patients subsequently treated with PARP inhibitors.
e17140 Background: PARP inhibitors are used alone or in combination with hormonal therapies for patients with HRR-mutated metastatic castrate resistant pr...
Association of MGMT status with survival in low and high-grade IDH-mutant astrocytomas.
2065 Background: The role of MGMT promoter methylation status on survival for IDH-mutant astrocytomas is less known than for glioblastoma, IDH-wildtype (G...
A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with 177Lu-DOTATATE to standard of care in patients after resection of neuroendocrine liver metastases (NELMAS).
TPS4225 Background: Gastro-entero-pancreatic (GEP) neuroendocrine tumours (NET) are steadily increasing in incidence and prevalence. About 65%-95% of GEP...
Complexities of managing refractory hypoglycemia in a rare case of metastatic grade 2 pancreatic neuroendocrine tumor.
e16361 Background: Pancreatic neuroendocrine tumors (pNETs) are often classified based on their ability to secrete hormones. While Insulinomas are the mos...
The impact of preoperative imaging strategies in EGFR-mutant non-small cell lung cancer (NSCLC): A multi-center retrospective review.
e20655 Background: ADAURA demonstrated an overall survival (OS) benefit with adjuvant osimertinib in Epidermal Growth Factor Receptor mutant (EGFR-mut) no...
Impact of body mass index on the pathological complete response among women with non-metastatic breast cancer treated with neoadjuvant chemotherapy in a tertiary cancer center in northern India.
e12627 Background: Late-stage presentation and locally advanced breast cancer forms a significant proportion of breast cancer (BC) burden in the India. Ne...
Phase II clinical study of the efficacy and safety of adebrelimab in combination with lenvatinib as second-line treatment for advanced intrahepatic cholangiocarcinoma.
e16215 Background: Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy with limited efficacy of second-line treatment following intole...
Phase II study of irinotecan liposome combined with 5-FU/LV + bevacizumab as first-line therapy in metastatic colorectal cancer: An early analysis from the study.
e15566 Background: FOLFIRI combined with bevacizumab is a standard treatment as first-line therapy in metastatic colorectal cancer (mCRC). Irinotecan lipo...
Whole-genome bisulfite sequencing of cell-free DNA to investigate molecular contributors to racial survival differences in advanced-stage triple-negative breast cancer.
3059 Background: Black women are twice as likely to be diagnosed with triple-negative breast cancer (TNBC), a highly aggressive and difficult-to-treat sub...
Socioeconomic disparities in palliative care utilization among children with late-stage bone and soft tissue sarcomas: A National Cancer Database analysis.
12066 Background: Palliative care seeks to improve the quality of life for many children living with cancer, but it remains underused. Racial and socioeco...
ACTIVATE: A pilot randomized activity coaching trial to increase vitality and energy during post-operative pelvic radiation therapy for endometrial cancer.
TPS12147 Background: The ASCO-Society for Integrative Oncology guidelines strongly recommend exercise as a therapeutic strategy for cancer-related fatigue...
Comparative efficacy and safety of donafenib versus bevacizumab in combination with immune checkpoint inhibitors and interventional therapy for advanced hepatocellular carcinoma: A retrospective cohort study.
e16305 Background: Advanced hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with a particularly high burden in Ch...
CheMo4METPANC: Combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreatic adenocarcinoma—Updated clinical and translational findings.
4167 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a uniformly fatal disease with an immunosuppressive tumor microenvironment (TME)....
Ovarian cancer in adolescents and young adults compared with older women: Prognostic factors, demographic characteristics, and survival along 2 decades in the US.
e17571 Background: Globally, among Adolescents and Young Adults (AYA) Ovarian Cancer (OC) has the #1 incidence and mortality in female cancers (Huang 2024...
Propensity-matched analysis of immunotherapy alone vs chemotherapy alone in stage II-IV colon cancer: Impact on cardiovascular, renal, and metastatic risks.
e15610 Background: Immune checkpoint inhibitors (ICIs) have revolutionized MSI-H/dMMR metastatic (stage IV) colon cancer treatment, but their real-world s...
Phase 2 study of pembrolizumab (pembro) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after progression on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on immune re-sensitization.
8560 Background: Immune checkpoint inhibitor (ICI)-based treatment regimens have become the standard of care for first-line treatment of EGFR/ALK wild-typ...